Oncology News

ZIOPHARM Oncology, Inc. today announced the unanimous approval of the National Institutes of Health's Recombinant DNA Advisory Committee for the initiation of a Phase 1 study of Ad-RTS-IL-12, an adenoviral vector engineered to express interleukin-12 under the control of veledimex, an oral activator, in subjects with recurrent or progressive ... (more)

Fowler High student Gabriel Rodriguez holds a present and Christmas poster he drew, as he and other members of the school's Redcat Men's Alliance wait to give the presents to young patients at Children's Hospital Central California, Friday afternoon, December 6, 2013.

One of hardest parts of a doctor's job - delivering bad news to patients and their loved ones - is rarely addressed in medical school.

The most-recognized oncology and hematology brand in North America is Epogen . The brand was most recognized by 4.9 percent of physicians in a survey conducted by Brand Institute Inc. during second-quarter 2013.

The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university.

Today Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability biomarkers for several cancers, in particular colorectal cancer .

The members of William House, who chose the Teenage Cancer Trust to be their charity following the death of fellow pupil Georgie Brock in 2009, raised the cash in just three years.

Hematologist and Oncologist Swati Sehgal has joined White Plains Hospital Physician Associates Oncology & Hematology, a division of the hospital aligning physicians with Hospital services.

Minister for Health James Reilly has said the salary and conditions of Director General of the HSE Tony O' Brien are perfectly in line with public pay policy.

IU Goshen Center for Cancer Care is using an advanced treatment called HIPEC which stands for Hyperthermic Intraperitoneal Chemotherapy.

Xiaowei Wang, PhD, and his colleagues have designed synthetic molecules that combine the advantages of two experimental RNA therapies against cancer.

The Triangle's two major cancer centers didn't make the list, but GlaxoSmithKline has lined up six other major global research institutions to collaborate on research into new ways to fight cancer using a mix of drugs.

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier , today announced that its lead oncology compound, ANG1005, a novel paclitaxel-peptide drug conjugate in development for breast cancer patients with brain metastasis and patients with primary brain cancer, and ANG4043, a ... (more)

Just 31% of the women with the disease survived for five years which was worse than poor nations like Bulgaria and Lithuania Research by The Lancet Oncology and analysed by the Daily Mirror found patients with the disease were more likely to die in the UK and Ireland than anywhere else in Europe.

To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

Cancer and blood disorder patients can now get faster care for their symptoms at an urgent care clinic that is now open in Winnipeg.

Florida-based Digital Blue Dog have signed an agreement to exclusively represent DBD's Oncology Network, creating the largest Oncology specific and patient-centric point-of-care network in the U.S. The two companies will still maintain operational independence while HMN will exclusively represent the combined network of nearly 15,000 high ... (more)

A sensitive new DNA test can predict how long ovarian cancer patients will survive, and guide personalized treatment decisions, according to new research.

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin A biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

The meeting will be held The studies highlight Eisai's current and ongoing clinical research efforts with eribulin mesylate, and reinforce the Company's commitment to metastatic breast cancer.